Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yang'erju Formula Granule (羊耳菊中药配方颗粒) is a standardized traditional Chinese medicine (TCM) preparation developed by Guizhou Yibai Pharmaceutical. It is derived from the medicinal herb *Inula cappa* (Buch.-Ham. ex D.Don) DC., commonly known as Yang'erju. The product is a concentrated granule formulation intended for oral administration after dissolution in water. Traditionally, *Inula cappa* is utilized for its anti-inflammatory, antitussive, and analgesic properties, often targeted at treating respiratory conditions such as bronchitis, tonsillitis, and the common cold. The development of this formula granule follows provincial standards in China, representing a modernization of traditional herbal decoctions to ensure consistent quality and patient convenience.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yang'erju Formula Granule.